节点文献
变应原淋巴结内注射免疫治疗变应性鼻炎临床指引
Clinical guidelines for intralymphatic immunotherapy for allergic rhinitis
【摘要】 变应原特异性免疫疗法（AIT）可减轻变应性鼻炎(AR)的症状，减少药物使用，阻断新发变应原，并改变过敏性疾病的进程。传统皮下免疫治疗和舌下免疫治疗的治疗周期长，患者依从性差，导致临床开展受限。近年来，国内外学者先后开展了多项淋巴结内注射(ILIT)变应原进行特异性免疫治疗AR的临床研究，取得了较好的疗效和安全性，且患者依从性明显增高，可作为AR患者免疫治疗的一种新选择。本文以螨变应原引起的AR为代表，介绍变应原淋巴结内注射免疫治疗的适应证、禁忌证、治疗方案、间隔时间、并发症及处理策略，为开展临床应用提供指引。
【Abstract】 Allergen-specific immunotherapy(AIT) has been shown to alleviate the severity of symptoms in patients with allergic rhinitis(AR), decrease dependence on symptomatic medications, lower the risk of developing new sensitivities to other inhalant allergens, and modify the progression of AR as well as potentially other allergic diseases. Traditionally, subcutaneous immunotherapy(SIT) requires multiple injections of the allergen over a period of 3 to 5 years. Sublingual immunotherapy(SLIT) has emerged as an alternative to SIT; however, it has not allowed for a reduction in treatment duration or dosing frequency. Recently, immunotherapy involving direct administration of allergens into lymph nodes(ILIT) has demonstrated promise as an innovative alternative. In this article, the immune therapy utilizing ILIT will be discussed especially in relation to AR caused by mite allergens,covering indications, contraindications, methodologies, and potential complications.
- 【文献出处】 中国眼耳鼻喉科杂志 ,Chinese Journal of Ophthalmology and Otorhinolaryngology , 编辑部邮箱 ,2025年01期
- 【分类号】R765.21
- 【下载频次】52